ALLELE: A phase 3 trial of a targeted treatment called tabelecleucel in people with post-transplant lymphoproliferative disorder
This trial is testing tabelecleucel in people with post-transplant lymphoproliferative disorder that has not responded after previous treatment.
You can share the following clinicaltrials.gov identifier with your medical team so they can find out more about the trial: NCT03394365
Trial aim and background
The aim of this trial is to find out whether tabelecleucel is a safe and effective treatment for people with Epstein-Barr virus positive post-transplant lymphoproliferative disorder (PTLD) that has not responded to treatment with rituximab or rituximab plus chemotherapy.
Everybody who takes part in this trial has treatment with tabelecleucel, if a suitable version of it is available for them.
Tabelecleucel is a type of treatment called an ‘allogeneic T cell immunotherapy’. It is made from donor T cells. The cells are tested in a lab to identify any that can recognise and kill cells infected with Epstein-Barr virus. These are called ‘Epstein-Barr virus cytotoxic T cells’ or EBV CTLs. The EBV CTLs are grown in a lab and then frozen until they are needed. EBV CTLs from different donors are available ‘off-the-shelf’. They are not made individually for each person.
Who can enter
Adults with Epstein-Barr positive PTLD that has not responded to rituximab or rituximab plus chemotherapy may be eligible for this trial. Your consultant can give you advice on whether you might be suitable for this trial.
Locations
Recruitment is taking place in the following UK locations:
- University Hospitals Birmingham NHS Foundation Trust, Birmingham
- King's College Hospital NHS Foundation Trust, London
- Imperial College Healthcare NHS Trust, London
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT03394365
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.